ARTICLE | Company News
ImmuLogic other research news
August 5, 1996 7:00 AM UTC
IMUL received a $700,000 Phase II SBIR from the National Institute on Drug Abuse to develop a vaccine to treat cocaine abuse. IMUL will use the funds to optimize the design of the vaccine and its admi...